

1 French translation and validation of the Synkinesis Assessment Questionnaire

2

3 **Authors**

4 Sarah Martineau MSc^{1,2}, Laurence Gascon MD^{2,3}, Mikhail Saltychev MD⁴, Akram Rahal MD³,

5 Karine Marcotte PhD^{1,2}, Sami P. Moubayed MD FRCSC^{2,3}

6 **Affiliations**

7 ¹ École d'orthophonie et d'audiologie, Université de Montréal, Montréal, Québec, Canada

8 ² Research Center of the Centre intégré universitaire de santé et services sociaux du Nord-de-
9 île-de-Montréal, Hôpital du Sacré-Coeur, Montréal, Canada

10 ³ Division of Otolaryngology – Head and Neck surgery, Université de Montréal, Montréal,
11 Canada

12 ⁴ Department of Physical and Rehabilitation Medicine, Turku University Hospital and University
13 of Turku, Turku, Finland

14 **Address correspondence to:**

15 Dr Sami-Pierre Moubayed

16 sp.moubayed@gmail.com

17 5400 boul. Gouin West, Montreal, Quebec, H4J 1C5

18

19 **Short title:** French Translation and Validation of SAQ Questionnaire

20

21 **Keywords:** Peripheral facial paralysis, Patient Reported Outcome Measure, Synkinesis,

22 Validation, French

23 **Financial disclosure:** None to declare

24

25 **Conflict of interest:** None to declare

26

27 **Funding:** This study did not receive any specific grant from funding agencies in the public,
28 commercial or not-for-profit sectors.

29

30 **Word count of Main Text: 1484**

31 **Word count of Abstract: 100**

32 Abstract

33 Synkinesis is a distressing sequela of peripheral facial palsy (PFP). This study aimed to
34 translate and validate the Synkinesis Assessment Questionnaire (SAQ), a reliable patient-
35 reported outcome evaluation tool for synkinesis, in French.

36 The SAQ was translated following a standard forward-backward translation procedure. After a
37 cognitive debriefing with 10 PFP patients, the SAQ-F was assessed amongst 50 patients for
38 internal consistency, known-group validity, construct validity, criterion validity and test-retest
39 reliability.

40 Results demonstrated that the SAQ-F was valid, reliable and had a unidimensional structure.

41 The SAQ-F should be accompanied by clinician-based scales, to provide valuable additional
42 information on the severity of synkinesis.

43 Facial synkinesis is among the most invalidating consequences of peripheral facial palsy (PFP).
44 It is defined as abnormal muscle contractions of one or many facial areas during volitional facial
45 movement¹. Synkinesis has numerous functional and cosmetic adverse effects as it limits
46 several day-to-day activities like speaking and eating². Potential mechanisms for the
47 development of synkinesis could be due to aberrant reinnervation, either by stimulation of
48 neighbor axons in the context of myelin loss or due to hyperexcitability of the facial nucleus¹.

49 From a research perspective, the use of a validated universal grading system for synkinesis
50 would allow appropriate data pooling and help in establishing valid recommendations for clinical
51 decision making³. From a clinical perspective, the evaluation of synkinesis through a patient-
52 reported outcome measure (PROM) is critical to grasp the scope of the handicap that it causes⁴.
53 Observer-based evaluation of facial function often leads to an incomplete description of patient
54 psychological distress and functional impairments that are caused by the sequelae of facial
55 palsy⁵.

56 The Synkinesis Assessment Questionnaire (SAQ)² was developed as a specific and validated
57 PROM for synkinesis. While the original English version has demonstrated to be a reliable and
58 valid instrument, there is no existing French equivalent. The purpose of the present study was to
59 create a validated French version of the SAQ in accordance with international guidelines of
60 translation and cultural adaptation.

61

62 The present study was approved by the ethics review board of the Centre-intégré-universitaire-
63 de-santé-et-de-services du Nord-de-l'Île-de-Montréal (MP-32-2020-1952). Written informed
64 consent was obtained from all participants.

65 The translation and cultural validation process respected international guidelines³. A standard
66 forward and backward-translation procedure was adopted, with two independent certified
67 translators who produced distinct translations from the original to the target language. Those
68 two translations were merged by the senior researcher of the study. A third translator back-
69 translated the reconciled version for review and identification of discrepancies.

70 The preliminary version was administered by the first author to 10 native French patients with
71 PFP (women: 8; mean age: 47.4 (15.6)) for cognitive debriefing³. Appropriate minor changes
72 were then made to the preliminary version and the resulting French version of the SAQ (SAQ-F)
73 was used for validation (Figure 1).

74 Validation of SAQ-F was conducted with a prospective cohort study including 25 patients with
75 PFP and 25 controls who visited the Otolaryngology clinic for other indications than a PFP (ear
76 infection, dysphonia, tonsillitis, etc.), from February to April 2020. Inclusion criteria were having
77 a PFP and being 18 years old and older. Exclusion criteria were: 1) history of neurological
78 disorders; 2) active psychiatric disease; 3) cognitive disorder; 4) inability to understand written
79 and oral French. For the PFP participants, the severity of facial palsy was assessed using the
80 Facial Nerve Grading System 2.0 (FNGS 2.0; also known as the House-Brackmann 2.0 score)⁶
81 and the Sunnybrook Facial Grading System (SB)⁷. These were chosen because each has been
82 shown to have high inter-observer agreement and validity⁸. Specific subscores of synkinesis can
83 be calculated from either scale to allow for more specific analyses. Patients completed the SAQ-
84 F twice within a two-week interval for test-retest reliability. None of the PFP patients were
85 subject to changes in their treatment.

86 Of 50 respondents, 25 were PFP patients and 25 controls (Table 1), with 20 men (40%) and 30
87 women (60%). The average age was 51.6 (18.4) years for the entire sample, 52.7 (18.6) years
88 in PFP and 50.6 (18.4) years in controls. The mean total SAQ score was 18.5 (95% CI 15.7 to

89 21.2, median 17, range 17-34) points in PFP group, and 9.0 (no variance) points in controls with
90 a difference of -9.5 (95% CI -12.2 to -6.8) points. and p -value <0.0001. Of the PFP patients,
91 80% were diagnosed with Bell's palsy and the remaining 20% were diagnosed with a PFP
92 secondary to Ramsay-Hunt's Syndrome, facial nerve schwannoma or traumatic injury. Severity
93 of facial palsy was generally rated as light to moderate with both FNGS 2.0 and SB scales:
94 mean FNGS 2.0 score was 9.4 (4.2) and mean SB score was 73.5 (21.5).

95

96 The analyses were performed using Stata/IC Statistical Software: Release 16. College Station
97 (StataCorp LP, TX, USA). The internal consistency of SAQ-F was assessed by using a
98 Chronbach's alpha along with its lower 95% confidence limit (95% CL). Alpha \geq 0.9 was
99 considered excellent, \geq 0.8 good, \geq 0.7 acceptable, \geq 0.6 questionable and \geq 0.5 poor. The known-
100 group validity (PFP vs. controls) was assessed by using a t-test for independent groups in case
101 of total score, and the Kruskal-Wallis nonparametric test for the items' ordinal scores. A two-
102 tailed p -value \leq 0.05 was considered statistically significant. The test-retest validity of the SAQ-F
103 scale was assessed by employing a Spearman rank correlation coefficient. Exploratory factor
104 analysis (EFA) was used to approximate the construct structure of the SAQ-F and included only
105 PFP patients. The goal was to determine whether the SAQ-F measures only one latent trait (=
106 signs of facial paralysis) or if there are other possible significant latent variables affecting the
107 results. The results were analyzed graphically. After the orthogonal varimax rotation was
108 applied, retained and excluded factors were explored visually on a scree plot along with a
109 parallel analysis. Pearson's product-moment correlation was used when comparing the SAQ-F
110 total score with the synkinesis subscores obtained from the Sunnybrook and FNGS 2.0 scales.
111 Fisher's transformation was used for both Spearman and Pearson's tests. Correlation <0.2 was
112 considered poor, from 0.21 to 0.4 fair, from 0.41 to 0.6 moderate, from 0.61 to 0.8 substantial,
113 and >0.8 perfect.

114 Results showed that the internal consistency of the SAQ-F was good with alpha of 0.87 (lower
115 95% CL 0.82). Results of the test-retest reliability were substantial to perfect for the total score
116 as well as for all nine items individually (0.96, 95% CI 0.93 to 0.98) (Table 2). Known-group
117 validity of SAQ-F appeared to be high as there were significant differences between groups in
118 the total score and in seven out of nine items' scores ($p < 0.01$) (Table 3). Construct validity of
119 the SAQ-F was tested by an exploratory factor analysis (Table 4 and Figure 2). The parallel
120 analysis of the scree plot showed that SAQ-F had three factors with positive eigenvalues above
121 the parallel analysis line. However, the eigenvalues of the second and third factors were as low
122 as 1.2 and 0.6 respectively and were disregarded for retaining. Thus, the SAQ-F was
123 considered to have a unidimensional structure with one factor, whose eigenvalue was 3.1.
124 When assessing the criterion validity based on the 25 PFP patients, Pearson's product-moment
125 correlation of the SAQ-F total score and the FNGS 2.0 synkinesis subscore was not significant
126 ($r = -0.23$; 95% CI: -0.57 to 0.18). The Spearman's rank correlation of SAQ-F total score with
127 Sunnybrook synkinesis subscore was also not significant ($r = -0.19$; 95% CI: -0.55 to 0.22).

128 In this study, we presented the translation and validation of the SAQ-F, a French patient-
129 centered questionnaire based on the original English SAQ². The SAQ scale allows to quantify
130 the patient's perception of synkinesis' severity and thus allows to adapt the management and
131 overall care of synkinesis, to fit the patient's expectations. Cross-cultural adaptation and
132 validation is necessary in the use of PROM questionnaires, to avoid misinterpretation while
133 using questionnaires developed in other countries³. To our knowledge, no other study validated
134 the SAQ scale in French. Thus, the SAQ-F will be highly relevant for many clinical and research
135 settings in Quebec and other French-speaking regions.

136 We translated and validated the SAQ-F according to the best practice's international
137 guidelines³. Our results showed that the SAQ-F has good internal consistency, a high test-retest
138 reliability, a high known-group validity, allowing to distinguish between controls and PFP

139 patients, as well as good construct validity. Compared to the original version, the SAQ-F
140 presented a slightly higher internal consistency (0.87 for SAQ-F and 0.80 for SAQ) and test-
141 retest reliability (0.96 in our study and 0.881 in the original one).

142 Correlations with synkinesis subscores of clinician-based questionnaires were not significant.
143 Other studies already reported discrepancies between PROM and clinician-based physical
144 examination⁵. A high correlation between both measures is probably not to be expected, and
145 both of them should be taken for a complete overview of the synkinesis severity^{2,1}.

146 This study is not without limitation. As the data comes from a small number of patients, non-
147 significant results regarding criterion validity could be due to lack of power. Due to practical
148 reasons, the group size was limited to 25 patients, which is nonetheless comparable with many
149 other PROM studies in the literature about PFP⁹. Further research may reveal valuable
150 information about SAQ-F psychometric properties by employing, for example, item response
151 theory analysis (IRT)¹⁰.

152 The SAQ-F was found to be a reliable, easy-to-use and valid unidimensional scale to assess
153 synkinesis after PFP. The SAQ-F should be accompanied by clinician-based scales to provide
154 valuable additional information on the severity of synkinesis.

155 **Acknowledgements:** The authors would like to thank Anne-Marie Chouinard for her
156 contribution in the development of the research protocol.

157 **Statement of Authorship:** SM & LG participated in the development of the research protocol,
158 recruitment of patients and the redaction of the article. AR and KM participated in the redaction
159 of the article. MS participated in the analysis of data and redaction of the article. SPM
160 supervised each step of the research.

161

162 **Figure Captions:**

SAQ

Veillez répondre aux questions suivantes concernant la fonction faciale du côté du visage atteint par la paralysie faciale, sur une échelle de 1 à 5, selon les classements suivants :

- 1 = rarement ou pas du tout
- 2 = occasionnellement, ou très légèrement
- 3 = parfois, ou légèrement
- 4 = la plupart du temps, ou modérément
- 5 = tout le temps, ou sévèrement


Question

Score (1 À 5)

- | | |
|--|-------|
| 1 Lorsque je souris, mon œil se ferme | _____ |
| 2 Lorsque je parle, mon œil se ferme | _____ |
| 3 Lorsque je siffle ou que j'arrondis les lèvres, mon œil ferme | _____ |
| 4 Lorsque je souris, mon cou se tend | _____ |
| 5 lorsque je ferme les yeux, mon visage se contracte | _____ |
| 6 lorsque je ferme les yeux, le coin de ma bouche bouge | _____ |
| 7 lorsque je ferme les yeux, mon cou se tend | _____ |
| 8 Lorsque je mange, mes yeux pleurent | _____ |
| 9 Lorsque je bouge mon visage, des creux apparaissent sur mon menton | _____ |

163

164 **Figure 1. Synkinesis Assessment Questionnaire- French**



165

166 Figure 2. Scree plot of the factor analysis along with parallel analysis of the SAQ-F for construct
167 validity

168

References

1. Kleiss IJ, Beurskens CHG, Stalmeier PFM, Ingels KJAO, Marres HAM. Synkinesis assessment in facial palsy: validation of the Dutch Synkinesis Assessment Questionnaire. *Acta Neurol Belg*. 2016;116(2):171-178.
2. Mehta RP, WernickRobinson M, Hadlock TA. Validation of the Synkinesis Assessment Questionnaire. *Laryngoscope*. 2007;117(5):923-926.
3. Wild D, Grove A, Martin M, et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. *Value Health*. 2005;8(2):94-104.
4. VanSwearingen JM, Cohn JF, Turnbull J, Mrzai T, Johnson P. Psychological distress: Linking impairment with disability in facial neuromotor disorders. *Otolaryngol Head Neck Surg*. 1998;118(6):790-796.
5. Marsk E, Hammarstedt-Nordenvall L, Engstrom M, Jonsson L, Hultcrantz M. Validation of a swedish version of the Facial Disability Index (FDI) and the Facial Clinimetric Evaluation (FaCE) scale. *Acta Otolaryngol*. 2013;133:662-669.
6. Vrabc JT, Backous DD, Djalilian HR, et al. Facial Nerve Grading System 2.0. *Otolaryngology and Head and Neck Surgery*. 2009;140:445-450.
7. Ross B, Fradet G, Nedzelski JM. Development of a sensitive clinical facial grading system. *Otolaryngol Head Neck Surg*. 1996;114:380-386.
8. Fattah AY, Gurusinghe AD, Gavilan J, et al. Facial nerve grading instruments: Systematic review of the literature and suggestion for uniformity. *Plastic Reconstructive Surgery*. 2015;135:569-579.
9. Luijmes RE, Pouwels S, Beurskens CH, Kleiss IJ, Siemann I, Ingels KJ. Quality of life before and after different treatment modalities in peripheral facial palsy: A systematic review. *Laryngoscope*. 2017;127(5):1044-1051.
10. Nguyen TH, Han HR, Kim MT, Chan KS. An introduction to item response theory for patient-reported outcome measurement. *Patient*. 2014;7(1):23-35.

Table 1. Patients demographics

	Controls						PFP patients					
	n	%	Mean	SD	Median	Range	n	%	Mean	SD	Median	Range
Gender												
Male	11	44					9	36				
Female	14	56					16	64				
Age (years)			50.6	18.4	56	23-90			52.7	18.6	53	19-95
Diagnosis												
Bells							20	80				
Ramsay Hunt							2	8				
Facial nerve Schwannoma							2	8				
Traumatic injury							1	4				

Side										
Left					11	44				
Right					14	56				
FNGS 2.0 total score							9.44	4.2	9	9-24
Sunnybrook total score							73.5	21.5	76	5-97
SAQ-F total score	9	0	9	9			18.5	17	17	34

Note: PFP= peripheral facial palsy; n = number; SD = standard deviation; Facial Nerve Grading Scale 2.0 (FNGS 2.0) scores: 24 = total palsy; 4 = no facial palsy. Sunnybrook (SB) scores: minimum possible = 0 or total palsy; maximum possible = 100% or normal; SAQ scores: 9 = no synkinesis; 45 = severe synkinesis.

Table 2. Test-retest validity of the SAQ-F (including both PFP and control groups)

	r	95%CI	
		Lower limit vs upper limit	
Total score	0.96	0.93	0.98
Item 1	0.78	0.65	0.87
Item 2	0.92	0.87	0.96
Item 3	0.93	0.88	0.96
Item 4	0.92	0.85	0.95
Item 5	0.69	0.51	0.81
Item 6	0.90	0.82	0.94
Item 7	0.60	0.38	0.75
Item 8	0.89	0.81	0.94
Item 9	0.81	0.69	0.89

Note: SAQ-F= Synkinesis Assessment Questionnaire – French; PFP = peripheral facial palsy;

CI = confidence interval .

Table 3. Know-group validity – differences in SAQ-F scores between PFP and control groups.

	<i>p</i> -value
Total score	<0.0001 ^a
Item 1	0.0002 ^b
Item 2	0.0015 ^b
Item 3	0.0006 ^b
Item 4	0.0033 ^b
Item 5	0.0015 ^b
Item 6	0.0001 ^b
Item 7	0.0500 ^b
Item 8	0.0041 ^b
Item 9	0.2207 ^b

Note: ^a Independent groups t-test; ^b Kruskal-Wallis test; SAQ-F= Synkinesis Assessment Questionnaire – French; PFP = peripheral facial palsy; CI = confidence interval .

Table 4. Rotated factor loadings (pattern matrix) and unique variances

Factors →	1	2	3	4	5	Uniqueness
Variable ↓						
Item 1	0.10	0.28	0.70	0.02	0.00	0.42
Item 2	0.10	0.87	0.21	-0.10	-0.09	0.16
Item 3	0.19	0.88	0.01	0.08	0.12	0.17
Item 4	0.68	0.12	0.44	0.13	0.08	0.30
Item 5	0.74	0.33	0.09	-0.04	0.08	0.33
Item 6	0.54	0.40	0.13	0.01	0.28	0.45
Item 7	0.84	0.05	-0.05	0.01	-0.07	0.28
Item 8	0.03	-0.15	0.05	-0.34	-0.01	0.86
Item 9	0.13	-0.18	0.19	0.44	0.01	0.72